Carvedilol Post-Intervention long-Term Administration in Large-scale Randomized Controlled Trial

Carvedilol Post-Intervention long-Term Administration in Large-scale Randomized Controlled Trial - CAPITAL-RCT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003256

Enrollment

1300

Registered

2010-03-31

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Carvedilol none Carvedilol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with STEMI after primary PCI 2)Patients with left ventricular ejection fraction more than or equal to 40%

Exclusion criteria

Exclusion criteria: 1)Patients with contraindication for beta-blocker 2)Patients with left ventricular ejection fraction less than 40% 3)Patients with implantable cardioverter defibrillators 4)Patients with end-stage malignancy

Design outcomes

Primary

Measure	Time frame
1)All cause mortality 2)Composite of death, myocardial infarction, acute coronary syndrome, heart failure hospitalization	—

Secondary

Measure	Time frame
1) Composite of death, myocardial infarction, stroke, acute coronary syndrome, heart failure hospitalization, any revascularization 2) Composite of cardiac death, myocardial infarction, stroke, acute coronary syndrome, heart failure hospitalization, any revascularization 3) Composite of cardiac death, myocardial infarction, stroke 4) Cardiac death 5) Sudden cardiac death 6) Cardiovascular death 7) Myocardial infarction 8) Acute coronary syndrome 9) Sustained ventricular tachycardia or ventricular fibrillation 10) Heart failure hospitalization 11) Stent thrombosis(ARC Definite) 12) Target vessel revascularization 13) Clinically-driven target-lesion revascularization 14) Any revascularization 15) Any clinically-driven coronary revascularization 16) Coronary artery bypass grafting 17) Stroke 18) Worsening of angina due to coronary spasm 19) Bleeding complications	—

Measure

Time frame

1) Composite of death, myocardial infarction, stroke, acute coronary syndrome, heart failure hospitalization, any revascularization 2) Composite of cardiac death, myocardial infarction, stroke, acute coronary syndrome, heart failure hospitalization, any revascularization 3) Composite of cardiac death, myocardial infarction, stroke 4) Cardiac death 5) Sudden cardiac death 6) Cardiovascular death 7) Myocardial infarction 8) Acute coronary syndrome 9) Sustained ventricular tachycardia or ventricular fibrillation 10) Heart failure hospitalization 11) Stent thrombosis(ARC Definite) 12) Target vessel revascularization 13) Clinically-driven target-lesion revascularization 14) Any revascularization 15) Any clinically-driven coronary revascularization 16) Coronary artery bypass grafting 17) Stroke 18) Worsening of angina due to coronary spasm 19) Bleeding complications

—

Countries

Japan

Contacts

Public ContactNeiko Ozasa

Kyoto University Hospital Department of Cardiovascular Medicine

nei126@kuhp.kyoto-u.ac.jp075-751-4255

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026